NRX Pharmaceuticals (NRXP) Change in Accured Expenses (2017 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Change in Accured Expenses of -$68000.0 for Q1 2026, up 79.82% year-over-year from -$37815.2 in Q1 2025, and down 107.45% quarter-over-quarter from $913000.0 in Q4 2025.
NRX Pharmaceuticals (NRXP) Change in Accured Expenses (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Change in Accured Expenses for 10 consecutive years, with -$68000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 79.82% year-over-year to -$68000.0; the TTM figure through Mar 2026 stood at $770000.0 (down 92.08% YoY), while the FY2025 annual figure was $501000.0, down 94.99% from the prior year.
- Change in Accured Expenses retreated to -$68000.0 in Q1 2026 per NRXP's latest filing, from $913000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $10.1 million in Q4 2024 and bottomed at -$1.3 million in Q3 2023.
- Historically, Change in Accured Expenses has averaged $755823.5 across 5 years, with a median of -$49000.0 in 2022.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 1011.32% — and 2024, when it surged 15655.38%.
- NRX Pharmaceuticals' Change in Accured Expenses stood at -$49000.0 in 2022, then sank by 32.65% to -$65000.0 in 2023, then soared by 15655.38% to $10.1 million in 2024, then tumbled by 90.97% to $913000.0 in 2025, then plunged by 107.45% to -$68000.0 in 2026.
- Business Quant data shows NRXP's Change in Accured Expenses at -$68000.0 in Q1 2026, $913000.0 in Q4 2025, and -$210000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | -232,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -68,000.00 |
| Mar 31, 2026 | -68,000.00 |
| Dec 31, 2025 | 913,000.00 |
| Dec 31, 2025 | 913,000.00 |
| Sep 30, 2025 | -210,000.00 |
| Sep 30, 2025 | -210,000.00 |
| Jun 30, 2025 | 135,000.00 |
| Jun 30, 2025 | 135,000.00 |
| Mar 31, 2025 | -337,000.00 |
| Mar 31, 2025 | -337,000.00 |
| Dec 31, 2024 | 10.11 Mn |
| Dec 31, 2024 | 10.11 Mn |
| Sep 30, 2024 | -936,000.00 |
| Sep 30, 2024 | -936,000.00 |
| Jun 30, 2024 | 884,000.00 |
| Jun 30, 2024 | 884,000.00 |
| Mar 31, 2024 | -54,000.00 |
| Mar 31, 2024 | -54,000.00 |
| Dec 31, 2023 | -65,000.00 |
| Dec 31, 2023 | -65,000.00 |